logo
Wildfire Recovery Tax Treatment Even With New Tax Exclusion Is Tricky

Wildfire Recovery Tax Treatment Even With New Tax Exclusion Is Tricky

Forbes22-07-2025
LOS ANGELES, CALIFORNIA - JANUARY 8: A firefighter battles the Palisades Fire while it burns homes ... More at Pacific Coast Highway amid a powerful windstorm on January 8, 2025 in Los Angeles, California. The fast-moving wildfire has grown to more than 2900-acres and is threatening homes in the coastal neighborhood amid intense Santa Ana Winds and dry conditions in Southern California. (Photo by)
It was huge news in December 2024 when Congress passed a tax law to many wildfire settlements tax free. The law expires at the end of 2025, and there's no sign of it being amended to cover 2026 and later recoveries. That's a worry for recent fires such as the LA fires of 2025. Litigation usually takes years to resolve. Yet fire victims usually have tax issues long before any lawsuit recovery. They include whether and how to claim a casualty loss on their taxes, and how various categories of insurance proceeds are taxed.
Which Fires, Does Yours Qualify?
The new federal law is a great benefit but among other limitations, it applies only for payments through the end of 2025. But what about California state taxes? As for California taxes, state law added temporary provisions to the California Revenue & Taxation Code that exclude from California income tax amounts received in connection with certain specific California wildfires (the Butte Fire (if the recovery is received from the Fire Victim Trust), the North Bay Fires (if the recovery is received from the Fire Victim Trust), the Thomas Fire, the Woolsey Fire, the Kincade Fire, and the Zogg Fire). Other fires were not covered, until now.
California's 2025 budget legislation expanded the California income tax exclusions that apply to certain wildfire recoveries received between January 1, 2021 and January 1, 2030. However, the new exclusion does have requirements that not all wildfire recoveries may satisfy. As noted, in the past, California passed state-level tax exclusions for recoveries related to specific wildfires. That often made the specific wildfire that affected your home or property controlling over whether you qualified to treat your wildfire recovery as tax free.
Then, on September 29, 2024, Governor Newsom vetoed two bills that would have granted state-level income tax exclusions to new wildfires. In his letter to the Legislature, Governor Newsom explained that he vetoed the bills, not because he disagreed with the idea that the recoveries should be tax-free for California tax purposes, but because he believed that a wildfire exclusion should be addressed more systematically as part of the annual budgeting process, not on a wildfire-by-wildfire basis where it would be more difficult to incorporate the exclusions into California's budget balancing efforts.
That helps to explain why the new California wildfire exclusion was included in the recently enacted S.B. 132, which was one of the bills recently passed as part of a larger budget deal between the Governor and the state legislature. S.B. 132 adds a new section to the California tax code, Section 17138.7. The new exclusion applies to all wildfire recoveries received by a California taxpayer between January 1, 2021, and January 1, 2030, regardless of the specific wildfire involved.
However, there is one very notable requirement for the new exclusion. Under the new exclusion, the recovery must be received from a 'settlement entity.' The new law defines the term 'settlement entity' to mean an entity 'approved by a class action settlement administrator.' This definition seems likely to have been intended to include the PG&E Fire Victim Trust. However, what about money you get from your insurance company? It seems unlikely that that kind of payment could be shoehorned into this defined term. The same for recoveries received in direct settlement with Southern California Edison or PG&E outside of a class action.
For taxpayers whose recoveries do not qualify for the new exclusion, the existing wildfire-by-wildfire exclusions remain in the California tax code, for at least a little while longer. Those exclusions are still alternative bases to claim a California tax exclusion for amounts received through 2026 or 2027, depending on the specific wildfire involved.
Does the new exclusion seem unduly narrow or formalistic, particularly for an exclusion that was presented as intending to expand the scope of wildfires that qualify for exclusion from California income tax? Yes, many fire victims are likely to think so. Of course, this is still a new law. It is possible that there may be guidance from the Franchise Tax Board about the application and requirements for claiming this exclusion.
Regarding federal taxes, tax issues can hinge on federal disaster declarations, and even determining which disaster declarations count can be nuanced.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Five9 Stock Was Flailing on Friday
Why Five9 Stock Was Flailing on Friday

Yahoo

timean hour ago

  • Yahoo

Why Five9 Stock Was Flailing on Friday

Key Points The company notched a double beat in its second quarter, but that wasn't good enough for the market. Investors seemed more concerned about a coming change in top management. 10 stocks we like better than Five9 › Contact center software solutions provider Five9 (NASDAQ: FIVN) has been having a forgettable Friday on the stock exchange. After the company published its latest set of quarterly results and announced a top-level managerial change, investors sold out of its stock to the point where it was down nearly 4% in late-session trading. That slide was notably more pronounced than the 1.7% decrease of the S&P 500 index. Double-digit improvements For its second quarter, Five9 posted a record-high revenue figure of over $283 million, which was 12% higher year over year. Artificial intelligence (AI) played a significant role in this, as the company's enterprise AI revenue advanced by 42% during the period. As for profitability, it also rose at a double-digit rate. Non-GAAP (adjusted) net income came in at over $58 million ($0.76 per share), well up from the nearly $39 million in the year-ago period. Analysts tracking the stock were expecting an adjusted net income figure of $0.62, on revenue of slightly more than $275. Five9 also proffered guidance for both its current (third) quarter and the entirety of 2025. For the latter period, it's modeling slightly over $1.14 billion to almost $1.15 billion for revenue, and adjusted net income ranging from $2.86 to $2.90 per share. The consensus analyst projections for the two metrics are a bit more than $1.14 billion and $0.70, respectively. Successful CEO is stepping down That double beat was good news, but this was obscured by the company's announcement that CEO Mike Burkland is retiring. He will stay in the job until a replacement is found. Burkland served as Five9's leader from 2008 to 2017, until he was diagnosed with cancer. He returned to the position in 2022. In its announcement of his departure, Five9 said that Buckland was at the helm of the company as it achieved notable milestones, and it credited him for growing it from $10 million to more than $1 billion in annual revenue. It's little wonder investors were displeased to hear of his looming departure. Do the experts think Five9 is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Five9 make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,036% vs. just 181% for the S&P — that is beating the market by 855.09%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Five9. The Motley Fool has a disclosure policy. Why Five9 Stock Was Flailing on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump Says He Will Get Drug Prices Down By 1500%
Trump Says He Will Get Drug Prices Down By 1500%

Forbes

time2 hours ago

  • Forbes

Trump Says He Will Get Drug Prices Down By 1500%

U.S. President Donald Trump is now promising to get pharmaceutical companies to significantly reduce the drug prices that they are charging Americans. On Thursday, the White House announced that Trump had just sent letters to the heads of 17 major pharmaceutical companies pushing them to cut the prices that Americans have to pay down to the levels that people in other countries pay. It's not clear yet by what amount—if any—this will eventually get pharmaceutical companies to reduce prescription medication prices for those in the U.S. But chances are any price reductions that end up occurring won't be anywhere near the 1500% that Trump has promised. Trump Spoke Of 600%, 1000% And 1500% Reductions in Drug Prices Yep, 1500% is the percentage that Trump mentioned in a July reception with members of Congress. 'This is something that nobody else can do,' Trump emphasized then. "We're gonna get the drug prices down. Not 30 or 40 percent, which would be great, not 50 or 60, no. We're gonna get 'em down 1,000 percent, 600 percent, 500 percent, 1,500 percent.' Here's a video of this posted on what used to be Twitter: Getting the prices of medications—or of anything that's sold by companies for that matter—down by more than 100% is certainly something that no one else has done. It's probably something you have never even dreamed of before, since for-profit companies are usually trying to make, you know, a profit. So, it's kind of true what Trump then subsequently said, 'We will have reduced drug prices by 1,000 percent, by 1,100, 1,200, 1,300, 1,400, 700, 600; not 30 or 40 or 50 percent but numbers the likes of which you've never even dreamed of before.' A video of this was also posted on X: Let's do the math. Say a bottle of a medication currently costs $100. A 25% price reduction would bring this cost down to $75. A 100% price reduction would make the medication completely free. Any reduction greater than 100% would presumably mean that the manufacturer would have to pay you. Thus, a 200% price reduction would result in a $100 payday per bottle for you. Holy, new way to earn money, Batman! If Trump can get you a 1500% reduction, hallelujah, time to replace filming YouTube videos with 'buying' medications as the way to make money. Now, the chances that the Trump administration will achieve a 1500% reduction in drug prices are probably a whole lot less than 100%. Getting pharmaceutical companies who have been enjooying very healthy profits for years to pay customers to take their drugs would be quite a trick. Plus, the pharmaceutical companies would have to change their advertisements so that instead of telling you that you may have a condition that you don't realize you have, the ads might say something like 'You're fine and don't have anything that pharmaceutical interventions can't fix. Please don't use our medications. We can't afford you to do so.' Trump Sent Letters To 17 Pharmaceutical Companies Outlining Steps To Reduce Drug Prices That 1500% number may not have been in the letters that Trump sent on Thursday to pharmaceutical manufacturers. Assuming that the letters had the right postage, they went to the leaders of AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. According to the White House, the letters listed steps to reduce the prices of prescription drugs in the U.S. 'to match the lowest price offered in other developed nations (known as the most-favored-nation, or MFN, price)' The steps are as follows: The letters asserted that there's been 'global freeloading on American pharmaceutical innovation' and did warn that if the outlined steps were't taken by the pharmaceutical companies the federal government "will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices." Trump Signed An Executive Order Regarding Drug Prices In May Pharmaceutical companies can now be 1500% sure that the Trump administration has them in its political line-of-sight. Back on May 12, Trump signed an Executive Order that asserted the following: 'The United States has less than five percent of the world's population and yet funds around three quarters of global pharmaceutical profits. This egregious imbalance is orchestrated through a purposeful scheme in which drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States.' That Executive Order indicated that the U.S. Secretary of Health and Human Services, which is currently Robert F. Kennedy, Jr., 'shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' Americans Do Pay Higher Drug Prices Than Those In Other Countries It is true that drug prices are typically significantly higher in the U.S. than in other countries. For example, a June 2024 publication in the RAND Health Quarterly described how drug prices in the U.S. were on average nearly three times higher than those in 33 other high-income countries. Over the past two decades, yearly rises in drug prices have easily outpaced inflation. A 2024 KFF poll showed that the majority of Americans are worried about prescription medication costs being too high. Such worries shouldn't be that surprising. Many prescription medications are not like mullets or fruitcakes. Taking them is often not a choice. Your well-being and even your life could literally depend on being able to afford the medication. And many pharmaceutical companies have shown no qualms about raising the price of medications as soon as they can. For example, even after receiving substantial funding from the U.S. government, Pfizer and Moderna quickly raised the prices of their COVID-19 vaccines as soon as the government wouldn't completely pay for them, as I described in Forbes in 2023. It is also true that talk about drug prices being too high in the U.S. is not new. Yet, none of the Presidential Administrations over the past two decades have done much to significantly alter these trends. I've written about state-wide efforts to reduce drug prices, such as Propostion 61 in California. But there's been a lack of more comprehensive efforts at the federal level to do so. The challenge is that a number of trends in the current U.S. system are contributing to higher drug prices. For example, mergers and acquisitions over the years have led to fewer, larger and more dominant pharmaceutical companies with less competition. Existing cost structures and requirements make it more difficult for new pharmaceutical companies to emerge and provide more competition. Cuts in funding and support for scientific research has made it harder and harder to develop new products. Fewer new products leave patients with fewer alternatives and existing products with less competition. Consumers and different purchasers have lacked negotiating power in general. At the same time, it seems like more and more people have been getting pieces of the drug price pie. This has included various middle people such as pharmacy benefits managers and different administrators. The marketing budgets of pharmaceutical companies have continued to grow as well. On top of that, investors have expected pharmaceutical companies to have ever increasing profitability. All of this means that a single simple intervention probably has a small percentage chance of reducing drug prices in a sustainable manner. Instead, a system approach may be needed, meaning multiple interventions at different points in the system that work together in a coordinated manner. Otherwise, there may be unintended consequences. A sustainable reduction in drug prices means one in which the math works out for all patients. You don't want a situation where the prices of some drugs are reduced while those of others are raised. You also don't want a situation where the costs end up being hidden.

Why Roku Stock Took a Dive Today
Why Roku Stock Took a Dive Today

Yahoo

time2 hours ago

  • Yahoo

Why Roku Stock Took a Dive Today

Key Points Roku posted solid growth on the top and bottom lines, but investors were still unsatisfied with the report. After it surged through May and June, investors seemed to think the stock had run too high. Roku's losses are improving, but investors typically demand faster growth from an unprofitable company. 10 stocks we like better than Roku › Shares of Roku (NASDAQ: ROKU) were tumbling today even though the leading streaming distribution platform topped headline estimates. Investors still seemed to find fault with key metrics in the quarter, as well as with its guidance and valuation. As a result, the stock was down 15.5% at 2:14 p.m. ET. Roku is moving in the right direction Roku is still losing money on a generally accepted accounting principles (GAAP) basis, but the company is making strides toward profitability. In the second quarter, Roku reported revenue of $1.11 billion, up 15% from the quarter a year ago, which was better than estimates at $1.07 billion. Revenue from devices was down 6% to $135.6 million, which could be a bad sign, as device sales help grow its customer base. Platform revenue, its core business, which is driven by advertising and subscription revenue share, was up 18% to $975.5 million. Streaming hours watched rose 17% to 35.4 billion, a positive trend for consumption. On the bottom line, the company showed improvement as adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 79% to $78.2 million. GAAP operating loss, meanwhile, narrowed from $71.2 million to $23.3 million. With the help of $28 million in other income from interest and strategic investments, Roku reported a GAAP per-share profit of $0.07, up from a loss in the quarter a year ago of $0.24 and better than estimates at a per-share loss of $0.16. Management credited its solid growth to "strong performance in video advertising and the successful acquisition of Frndly," as well as new ad tech integrations, including with Amazon. What's next for Roku Looking ahead, Roku expects $1.205 billion in revenue for the third quarter, or 13% growth, though that was ahead of the consensus at $1.17 billion. Its full-year revenue guidance of $4.65 billion was slightly below the average estimate at $4.66 billion. The company also announced a $400 million share buyback program. Overall, the results weren't the kind that typically lead to a double-digit decline. However, investors seem frustrated with Roku's operating losses and its valuation, considering it's expected to grow only in the low teens to midteens for the rest of the year. The stock soared in May and June, benefiting from the broader market recovery and its new ad partnership with Amazon. In that context, today's pullback seems to be more of a reset than a new trend in the stock. Should you buy stock in Roku right now? Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Jeremy Bowman has positions in Amazon and Roku. The Motley Fool has positions in and recommends Amazon and Roku. The Motley Fool has a disclosure policy. Why Roku Stock Took a Dive Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store